4 Pharmaceuticals Stocks to Sell Now

Advertisement

The ratings of 4 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This is a rough week for Merck & Co., Inc. (MRK). The company’s rating falls to D from the previous week’s C. Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of MRK stock.

This week, Mylan N.V. (MYL) drops from a D to a F rating. Mylan N.V. is a global generic and specialty pharmaceuticals company. The company also gets F’s in earnings growth. For more information, get Portfolio Grader’s complete analysis of MYL stock.

Alcobra Ltd. (ADHD) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of ADHD stock.

DURECT Corporation (DRRX) experiences a ratings drop this week, going from last week’s D to a F. DURECT Corporation is a specialty pharmaceutical company that develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of DRRX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/06/4-pharmaceuticals-stocks-to-sell-now-2/.

©2024 InvestorPlace Media, LLC